Cargando…

Higher incidence rates than previously known in tenosynovial giant cell tumors: A nationwide study in The Netherlands

Background and purpose — Tenosynovial giant cell tumors (TGCT) are rare, benign tumors, arising in synovial lining of joints, tendon sheaths, or bursae. 2 types are distinguished: localized, either digits or extremity, and diffuse lesions. Current TGCT incidence is based on 1 single US-county study...

Descripción completa

Detalles Bibliográficos
Autores principales: Mastboom, Monique J L, Verspoor, Floortje G M, Verschoor, Arjan J, Uittenbogaard, Daniël, Nemeth, Banne, Mastboom, Walter J B, Bovée, Judith V M G, Dijkstra, P D Sander, Schreuder, H W Bart, Gelderblom, Hans, Van de Sande, Michiel A J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694816/
https://www.ncbi.nlm.nih.gov/pubmed/28787222
http://dx.doi.org/10.1080/17453674.2017.1361126
_version_ 1783280206079852544
author Mastboom, Monique J L
Verspoor, Floortje G M
Verschoor, Arjan J
Uittenbogaard, Daniël
Nemeth, Banne
Mastboom, Walter J B
Bovée, Judith V M G
Dijkstra, P D Sander
Schreuder, H W Bart
Gelderblom, Hans
Van de Sande, Michiel A J
author_facet Mastboom, Monique J L
Verspoor, Floortje G M
Verschoor, Arjan J
Uittenbogaard, Daniël
Nemeth, Banne
Mastboom, Walter J B
Bovée, Judith V M G
Dijkstra, P D Sander
Schreuder, H W Bart
Gelderblom, Hans
Van de Sande, Michiel A J
author_sort Mastboom, Monique J L
collection PubMed
description Background and purpose — Tenosynovial giant cell tumors (TGCT) are rare, benign tumors, arising in synovial lining of joints, tendon sheaths, or bursae. 2 types are distinguished: localized, either digits or extremity, and diffuse lesions. Current TGCT incidence is based on 1 single US-county study in 1980, with an incidence of 9 and 2 per million person-years in localized (including digits) and diffuse TGCT, respectively. We aim to determine nationwide and worldwide incidence rates (IR) in TGCT affecting digits, localized-extremity TGCT and diffuse-type TGCT. Material and methods — Over a 5-year period, the Dutch Pathology Registry (PALGA) identified 4,503 pathology reports on TGCT. Reports affecting digits were solely used for IR calculations. Reports affecting extremities were clinically evaluated. Dutch IRs were converted to world population IRs. Results — 2,815 (68%) digits, 933 (23%) localized-extremity and 390 (9%) diffuse-type TGCT were identified. Dutch IR in digits, localized-extremity, and diffuse-type TGCT was 34, 11 and 5 per million person-years, respectively. All 3 groups showed a female predilection and highest number of new cases in age category 40–59 years. The knee joint was most often affected: localized-extremity (46%) and diffuse-type (64%) TGCT, mostly treated with open resection: localized (65%) and diffuse (49%). Reoperation rate due to local recurrence for localized-extremity was 9%, and diffuse TGCT 23%. Interpretation — This first nationwide study and detailed analyses of IRs in TGCT estimated a worldwide IR in digits, localized-extremity and diffuse TGCT of 29, 10, and 4 per million person-years, respectively. Recurrence rate in diffuse type is 2.6 times higher, compared with localized extremity. TGCT is still considered a rare disease; however, it is more common than previously understood.
format Online
Article
Text
id pubmed-5694816
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-56948162017-11-27 Higher incidence rates than previously known in tenosynovial giant cell tumors: A nationwide study in The Netherlands Mastboom, Monique J L Verspoor, Floortje G M Verschoor, Arjan J Uittenbogaard, Daniël Nemeth, Banne Mastboom, Walter J B Bovée, Judith V M G Dijkstra, P D Sander Schreuder, H W Bart Gelderblom, Hans Van de Sande, Michiel A J Acta Orthop Miscellaneous Background and purpose — Tenosynovial giant cell tumors (TGCT) are rare, benign tumors, arising in synovial lining of joints, tendon sheaths, or bursae. 2 types are distinguished: localized, either digits or extremity, and diffuse lesions. Current TGCT incidence is based on 1 single US-county study in 1980, with an incidence of 9 and 2 per million person-years in localized (including digits) and diffuse TGCT, respectively. We aim to determine nationwide and worldwide incidence rates (IR) in TGCT affecting digits, localized-extremity TGCT and diffuse-type TGCT. Material and methods — Over a 5-year period, the Dutch Pathology Registry (PALGA) identified 4,503 pathology reports on TGCT. Reports affecting digits were solely used for IR calculations. Reports affecting extremities were clinically evaluated. Dutch IRs were converted to world population IRs. Results — 2,815 (68%) digits, 933 (23%) localized-extremity and 390 (9%) diffuse-type TGCT were identified. Dutch IR in digits, localized-extremity, and diffuse-type TGCT was 34, 11 and 5 per million person-years, respectively. All 3 groups showed a female predilection and highest number of new cases in age category 40–59 years. The knee joint was most often affected: localized-extremity (46%) and diffuse-type (64%) TGCT, mostly treated with open resection: localized (65%) and diffuse (49%). Reoperation rate due to local recurrence for localized-extremity was 9%, and diffuse TGCT 23%. Interpretation — This first nationwide study and detailed analyses of IRs in TGCT estimated a worldwide IR in digits, localized-extremity and diffuse TGCT of 29, 10, and 4 per million person-years, respectively. Recurrence rate in diffuse type is 2.6 times higher, compared with localized extremity. TGCT is still considered a rare disease; however, it is more common than previously understood. Taylor & Francis 2017-11 2017-08-08 /pmc/articles/PMC5694816/ /pubmed/28787222 http://dx.doi.org/10.1080/17453674.2017.1361126 Text en © 2017 The Author(s). Published by Taylor & Francis on behalf of the Nordic Orthopedic Federation. https://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)
spellingShingle Miscellaneous
Mastboom, Monique J L
Verspoor, Floortje G M
Verschoor, Arjan J
Uittenbogaard, Daniël
Nemeth, Banne
Mastboom, Walter J B
Bovée, Judith V M G
Dijkstra, P D Sander
Schreuder, H W Bart
Gelderblom, Hans
Van de Sande, Michiel A J
Higher incidence rates than previously known in tenosynovial giant cell tumors: A nationwide study in The Netherlands
title Higher incidence rates than previously known in tenosynovial giant cell tumors: A nationwide study in The Netherlands
title_full Higher incidence rates than previously known in tenosynovial giant cell tumors: A nationwide study in The Netherlands
title_fullStr Higher incidence rates than previously known in tenosynovial giant cell tumors: A nationwide study in The Netherlands
title_full_unstemmed Higher incidence rates than previously known in tenosynovial giant cell tumors: A nationwide study in The Netherlands
title_short Higher incidence rates than previously known in tenosynovial giant cell tumors: A nationwide study in The Netherlands
title_sort higher incidence rates than previously known in tenosynovial giant cell tumors: a nationwide study in the netherlands
topic Miscellaneous
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694816/
https://www.ncbi.nlm.nih.gov/pubmed/28787222
http://dx.doi.org/10.1080/17453674.2017.1361126
work_keys_str_mv AT mastboommoniquejl higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands
AT verspoorfloortjegm higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands
AT verschoorarjanj higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands
AT uittenbogaarddaniel higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands
AT nemethbanne higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands
AT mastboomwalterjb higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands
AT boveejudithvmg higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands
AT dijkstrapdsander higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands
AT schreuderhwbart higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands
AT gelderblomhans higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands
AT vandesandemichielaj higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands
AT higherincidenceratesthanpreviouslyknownintenosynovialgiantcelltumorsanationwidestudyinthenetherlands